Lanzkowsky P, Shende A, Aral I, Saluja G
Arch Dis Child. 1975 Sep;50(9):685-90. doi: 10.1136/adc.50.9.685.
Lanzkowsky, P., Shende, A., Aral, I., Saluja, G. (1975). Archives of Disease in Childhood, 50, 685. Organ irradiation and combination chemotherapy in treatment of acute lymphocytic leukaemia in children. A total of 30 consecutive children with acute lymphocytic leukaemia (ALL) were treated from June 1971 until December 1974. Remission was induced with the use of vincristine and prednisone. After induction of remission, cranial irradiation and intrathecal methotrexate were given. Then the liver, spleen, and kidney were irradiated and 6-mercaptopurine, cyclophosphamide, and methotrexate were administered during the maintenance phase. Pulsed doses of vincristine and prednisone were administered at 10- to 12-week intervals. The patients were subdivided into two groups based on their initial white blood cell (WBC) counts: a standard risk group with an initial WBC count of less than 25 000/mm3 (25 X 10(9)/1) and a high risk group with an initial WBC count greater than 25 000/mm3 (25 X 10(9)/1). Of the 30 children entered in this study one standard risk patient died in the induction phase before attaining remission. Analysis of the results is therefore based on the remaining 29 patients, 22 standard risk and 7 high risk patients, who attained complete remission. Survival rates in continuous remission were found to be 43% of the high risk group, 88% for the standard risk group, and 77% for the combined group. Analysis of the data indicates that this therapy is unsatisfactory in high risk ALL. The results to date of this therapy for standard risk are sufficiently encouraging to continue its use in this subgroup of patients.
兰兹科夫斯基,P.,申德,A.,阿拉尔,I.,萨卢贾,G.(1975年)。《儿童疾病档案》,第50卷,第685页。器官照射与联合化疗治疗儿童急性淋巴细胞白血病。1971年6月至1974年12月,共连续治疗了30例急性淋巴细胞白血病(ALL)患儿。使用长春新碱和泼尼松诱导缓解。诱导缓解后,进行颅脑照射和鞘内注射甲氨蝶呤。然后对肝脏、脾脏和肾脏进行照射,并在维持阶段给予6-巯基嘌呤、环磷酰胺和甲氨蝶呤。每隔10至12周给予脉冲剂量的长春新碱和泼尼松。根据患者初始白细胞(WBC)计数将其分为两组:初始WBC计数低于25000/mm³(25×10⁹/L)的标准风险组和初始WBC计数高于25000/mm³(25×10⁹/L)的高风险组。在本研究纳入的30名儿童中,1名标准风险患者在诱导阶段未达到缓解前死亡。因此,结果分析基于其余29名达到完全缓解的患者,其中22名标准风险患者和7名高风险患者。发现高风险组持续缓解的生存率为43%,标准风险组为88%,联合组为77%。数据分析表明,这种疗法在高风险ALL中效果不理想。该疗法对标准风险患者迄今为止的结果足以令人鼓舞,可继续在这一亚组患者中使用。